Session 10: Mechanisms of HHT

10 Jun 2017
1:30 pm – 3:15 pm
Soderini Ballroom II, III

Session 10: Mechanisms of HHT

Invited Speaker:  Dr. Philippe Marambaud  (1:30pm – 2:15pm)

Therapeutic Potential of ALK1 Activating Drugs in HHT Models

 

Oral Presentations

2:15pm – 2:30pm

Decreased expression of VEGFR1 contributes to the pathogenesis of Hereditary Hemorrhagic Telangiectasia type 2

Lebrin F, Thalgott J, Dos-Santos-Luis D, Hosman AE, Martin S, Bracquart D, Srun S, Lamandé N, Carette MF, Oh SP, Westermann CJ, Snijder RJ, Mager JJ, Mummery CL, Rabelink TJ, Raymond K

 

2:30pm – 2:45pm

Nitric oxide synthase inhibition attenuates Notch-mediated brain arteriovenous malformation   

Wang R, Huang L

 

2:45pm – 3:00pm

Overexpression of alk1 in endothelial cells suppresses development of arteriovenous malformations in HHT mouse models

Oh SP, Kim YH, Phuong NV, Arthur HM, Lee YJ

 

3:00pm – 3:15pm

Identification of new genes and genetic modifiers in HHT that alter clinical severity

Wooderchak-Donahue W, Chen T, McDonald J, Whitehead K, Bayrak-Toydemir P